Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic factors of subfoveal polypoidal choroidal vasculopathy treated with intravitreal bevacizumab monotherapy
TCTR20241227005Completed
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Single-arm trial of bevacizumab in polypoidal choroidal vasculopathy (PCV), sponsored by None. Started Aug 2023; status: completed.
02
Drugs
bevacizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on TCTR20241227005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241227005.